Here, we have shown in NAFLD subjects that SDP lowered TG, as previously reported [49], and this occurred through a decreased VLDL-P output from the liver, consistent with the Apo B reduction also detected. This evidence concerns the gene APOB and metabolic dysfunction-associated steatotic liver disease.